Drystone LLC Acquires New Shares in Pfizer Inc. (NYSE:PFE)

Drystone LLC purchased a new stake in Pfizer Inc. (NYSE:PFE - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm purchased 145,800 shares of the biopharmaceutical company's stock, valued at approximately $3,868,000. Pfizer accounts for about 3.9% of Drystone LLC's investment portfolio, making the stock its 11th biggest holding.

Other institutional investors and hedge funds have also modified their holdings of the company. Retirement Wealth Solutions LLC bought a new stake in shares of Pfizer in the fourth quarter valued at approximately $26,000. Gladius Capital Management LP boosted its holdings in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company's stock valued at $30,000 after purchasing an additional 38,015 shares during the period. Quarry LP acquired a new stake in Pfizer in the 2nd quarter worth $31,000. Teachers Insurance & Annuity Association of America bought a new position in shares of Pfizer during the 3rd quarter worth about $35,000. Finally, Joseph Group Capital Management lifted its stake in shares of Pfizer by 168.3% in the third quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company's stock valued at $36,000 after buying an additional 771 shares during the period. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

PFE has been the subject of a number of research reports. Guggenheim reduced their price objective on Pfizer from $35.00 to $33.00 and set a "buy" rating for the company in a research report on Wednesday, December 11th. Wolfe Research assumed coverage on Pfizer in a research note on Friday, November 15th. They issued an "underperform" rating and a $25.00 price objective on the stock. Citigroup lowered their price target on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a research report on Tuesday. StockNews.com cut Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Finally, Sanford C. Bernstein assumed coverage on shares of Pfizer in a research report on Thursday, October 17th. They set a "market perform" rating and a $32.00 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and an average target price of $31.92.

Pfizer Trading Up 1.0 %

Shares of NYSE:PFE traded up $0.27 during trading on Thursday, hitting $26.89. 32,250,943 shares of the company's stock were exchanged, compared to its average volume of 35,832,922. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The firm has a market cap of $152.41 billion, a P/E ratio of 36.34, a PEG ratio of 0.64 and a beta of 0.64. The firm has a 50-day moving average price of $26.22 and a two-hundred day moving average price of $27.90. Pfizer Inc. has a 1-year low of $24.48 and a 1-year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 EPS for the quarter, topping analysts' consensus estimates of $0.64 by $0.42. The firm had revenue of $17.70 billion during the quarter, compared to analyst estimates of $14.92 billion. Pfizer had a net margin of 7.07% and a return on equity of 16.28%. The business's quarterly revenue was up 31.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.17) EPS. Equities analysts predict that Pfizer Inc. will post 2.94 earnings per share for the current year.

Pfizer Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be issued a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.40%. The ex-dividend date of this dividend is Friday, January 24th. This is an increase from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio is currently 227.03%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.